Cover Image

Tualang honey formulation as potential osteoarthritis treatment: in-vitro cytotoxicity outcome

INTRODUCTION: Osteoarthritis (OA) is a degenerative joint disease affecting millions worldwide. In the orthopaedic field, viscosupplementation is widely used as an option treatment for pain relief among osteoarthritis patients as it acts as a lubricant in the joints. Tualang Honey Formulation (THF...

Full description

Saved in:
Bibliographic Details
Main Authors: Zulkifly, Ahmad Hafiz, Abd. Rahim, Nour El Huda, Mohd Jan, Nurul Hafiza, Mohamad Amri, Nur Fathonah, Ibrahim, Mohd Zulfadzli, Hassan, Habibah, Rajab, Nor Fadilah
Format: Article
Language:English
Published: Malaysian Orthopaedic Association 2024
Subjects:
R Medicine (General)
RD Surgery
RD701 Orthopedics
Online Access:http://irep.iium.edu.my/116542/13/116542_%20Tualang%20honey%20formulation%20as%20potential%20Osteoarthritis.pdf
http://irep.iium.edu.my/116542/
https://www.morthoj.org/supplements/moa-2024/Poster/Ortho-Research/ER05.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.iium.irep.116542
record_format dspace
spelling my.iium.irep.1165422024-12-10T06:32:19Z http://irep.iium.edu.my/116542/ Tualang honey formulation as potential osteoarthritis treatment: in-vitro cytotoxicity outcome Zulkifly, Ahmad Hafiz Abd. Rahim, Nour El Huda Mohd Jan, Nurul Hafiza Mohamad Amri, Nur Fathonah Ibrahim, Mohd Zulfadzli Hassan, Habibah Rajab, Nor Fadilah R Medicine (General) RD Surgery RD701 Orthopedics INTRODUCTION: Osteoarthritis (OA) is a degenerative joint disease affecting millions worldwide. In the orthopaedic field, viscosupplementation is widely used as an option treatment for pain relief among osteoarthritis patients as it acts as a lubricant in the joints. Tualang Honey Formulation (THF), a patented (patent no. MY179303-A) viscosupplement, is being investigated as a potential treatment for OA. This study aimed to evaluate the biocompatibility of THF by assessing cell viability upon exposure. MATERIALS & METHODS: A dose-response cytotoxicity of THF was evaluated in V79-4 cells. The THF was dissolved in a two-times complete growth medium at the concentration of 50% v/v. A serial 2-fold dilution was carried out using a complete growth medium prior to exposure towards cells. Cells were exposed to serially diluted Tualang Honey Formulation (THF) concentrations (1.56% to 50% v/v) for 24 hours. The cytotoxicity was determined by accessing the cell viability through the reduction of tetrazolium salts (MTT). Cell viability was obtained by dividing the mean optical density (OD) values of the THF with the mean OD of negative control and multiplied by 100. RESULTS AND DISCUSSIONS: V79-4 cells were used to study the cytotoxicity of THF. As shown in Table 1, the viability of the cell treated with the THF was more than 73% in all concentrations. Figure 1 shows the cell viability of THF at all concentrations. The outcomes of this study showed there was no toxicity for THF even at higher concentrations, which demonstrated that THF can be used safely and applied in OA as a potential viscosupplement. CONCLUSION: The present study revealed that THF did not demonstrate a cytotoxic effect when exposed to the cell. This outcome shows that THF is biocompatible and is a potential candidate for osteoarthritis treatment in future. Malaysian Orthopaedic Association 2024-07 Article PeerReviewed application/pdf en http://irep.iium.edu.my/116542/13/116542_%20Tualang%20honey%20formulation%20as%20potential%20Osteoarthritis.pdf Zulkifly, Ahmad Hafiz and Abd. Rahim, Nour El Huda and Mohd Jan, Nurul Hafiza and Mohamad Amri, Nur Fathonah and Ibrahim, Mohd Zulfadzli and Hassan, Habibah and Rajab, Nor Fadilah (2024) Tualang honey formulation as potential osteoarthritis treatment: in-vitro cytotoxicity outcome. Malaysian Orthopaedic Journal, 17 (Suppl. A). ISSN 1985-2533 E-ISSN 2232-111X https://www.morthoj.org/supplements/moa-2024/Poster/Ortho-Research/ER05.pdf
institution Universiti Islam Antarabangsa Malaysia
building IIUM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider International Islamic University Malaysia
content_source IIUM Repository (IREP)
url_provider http://irep.iium.edu.my/
language English
topic R Medicine (General)
RD Surgery
RD701 Orthopedics
spellingShingle R Medicine (General)
RD Surgery
RD701 Orthopedics
Zulkifly, Ahmad Hafiz
Abd. Rahim, Nour El Huda
Mohd Jan, Nurul Hafiza
Mohamad Amri, Nur Fathonah
Ibrahim, Mohd Zulfadzli
Hassan, Habibah
Rajab, Nor Fadilah
Tualang honey formulation as potential osteoarthritis treatment: in-vitro cytotoxicity outcome
description INTRODUCTION: Osteoarthritis (OA) is a degenerative joint disease affecting millions worldwide. In the orthopaedic field, viscosupplementation is widely used as an option treatment for pain relief among osteoarthritis patients as it acts as a lubricant in the joints. Tualang Honey Formulation (THF), a patented (patent no. MY179303-A) viscosupplement, is being investigated as a potential treatment for OA. This study aimed to evaluate the biocompatibility of THF by assessing cell viability upon exposure. MATERIALS & METHODS: A dose-response cytotoxicity of THF was evaluated in V79-4 cells. The THF was dissolved in a two-times complete growth medium at the concentration of 50% v/v. A serial 2-fold dilution was carried out using a complete growth medium prior to exposure towards cells. Cells were exposed to serially diluted Tualang Honey Formulation (THF) concentrations (1.56% to 50% v/v) for 24 hours. The cytotoxicity was determined by accessing the cell viability through the reduction of tetrazolium salts (MTT). Cell viability was obtained by dividing the mean optical density (OD) values of the THF with the mean OD of negative control and multiplied by 100. RESULTS AND DISCUSSIONS: V79-4 cells were used to study the cytotoxicity of THF. As shown in Table 1, the viability of the cell treated with the THF was more than 73% in all concentrations. Figure 1 shows the cell viability of THF at all concentrations. The outcomes of this study showed there was no toxicity for THF even at higher concentrations, which demonstrated that THF can be used safely and applied in OA as a potential viscosupplement. CONCLUSION: The present study revealed that THF did not demonstrate a cytotoxic effect when exposed to the cell. This outcome shows that THF is biocompatible and is a potential candidate for osteoarthritis treatment in future.
format Article
author Zulkifly, Ahmad Hafiz
Abd. Rahim, Nour El Huda
Mohd Jan, Nurul Hafiza
Mohamad Amri, Nur Fathonah
Ibrahim, Mohd Zulfadzli
Hassan, Habibah
Rajab, Nor Fadilah
author_facet Zulkifly, Ahmad Hafiz
Abd. Rahim, Nour El Huda
Mohd Jan, Nurul Hafiza
Mohamad Amri, Nur Fathonah
Ibrahim, Mohd Zulfadzli
Hassan, Habibah
Rajab, Nor Fadilah
author_sort Zulkifly, Ahmad Hafiz
title Tualang honey formulation as potential osteoarthritis treatment: in-vitro cytotoxicity outcome
title_short Tualang honey formulation as potential osteoarthritis treatment: in-vitro cytotoxicity outcome
title_full Tualang honey formulation as potential osteoarthritis treatment: in-vitro cytotoxicity outcome
title_fullStr Tualang honey formulation as potential osteoarthritis treatment: in-vitro cytotoxicity outcome
title_full_unstemmed Tualang honey formulation as potential osteoarthritis treatment: in-vitro cytotoxicity outcome
title_sort tualang honey formulation as potential osteoarthritis treatment: in-vitro cytotoxicity outcome
publisher Malaysian Orthopaedic Association
publishDate 2024
url http://irep.iium.edu.my/116542/13/116542_%20Tualang%20honey%20formulation%20as%20potential%20Osteoarthritis.pdf
http://irep.iium.edu.my/116542/
https://www.morthoj.org/supplements/moa-2024/Poster/Ortho-Research/ER05.pdf
_version_ 1818833720471191552
score 13.235796

Similar Items